Literature DB >> 33272926

Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer.

Fei Wang1,2, Wei Zheng1, Christina E Bailey3, Ingrid A Mayer4, Jennifer A Pietenpol5, Xiao-Ou Shu6.   

Abstract

It is unclear whether racial/ethnic disparities in triple-negative breast cancer (TNBC) mortality remain after accounting for clinical characteristics, treatment, and access-to-care-related factors. In this study, women with a primary diagnosis of TNBC during 2010-2014 were identified from the National Cancer Database. Hazard ratios (HR) and 95% confidence intervals (CI) for 3- and 5-year all-cause mortality associated with race/ethnicity were estimated using Cox proportional hazards models with stepwise adjustments for age, clinical characteristics, treatment, and access-to-care-related factors. Of 78,708 patients, non-Hispanic (NH) black women had the lowest 3-year overall survival rates (79.4%), followed by NH-whites (83.1%), Hispanics (86.0%), and Asians (87.1%). After adjustment for clinical characteristics, NH-blacks had a 12% higher risk of dying 3 years post-diagnosis (HR, 1.12; 95% CI, 1.07-1.17), whereas Hispanics and Asians had a 24% (HR, 0.76; 95% CI, 0.70-0.83) and 17% (HR, 0.83; 95% CI, 0.73-0.94) lower risk than their NH-white counterparts. The black-white disparity became non-significant after combined adjustment for treatment and access-to-care-related factors (HR, 1.04; 95% CI, 0.99-1.09), whereas the white-Hispanic and white-Asian differences remained. Stratified analyses revealed that among women aged less than or equal to 50 with stage III cancer, the elevated risk among NH-blacks persisted (HR, 1.20; 95% CI, 1.04-1.39) after full adjustments. Similar results were seen for 5-year mortality. Overall, clinical characteristics, treatment, and access-to-care-related factors accounted for most of the white-black differences in all-cause mortality of TNBC but explained little about Hispanic- and Asian-white differences. SIGNIFICANCE: These findings highlight the need for equal healthcare to mitigate the black-white disparity and for investigations of contributors beyond healthcare for lower mortality among Asians and Hispanics. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33272926     DOI: 10.1158/0008-5472.CAN-20-3094

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer.

Authors:  Mao-Shan Chen; Peng-Cheng Liu; Jin-Zhi Yi; Li Xu; Tao He; Hao Wu; Ji-Qiao Yang; Qing Lv
Journal:  Sci Rep       Date:  2022-08-29       Impact factor: 4.996

2.  Racial and Ethnic Inequality in Survival Outcomes of Women With Triple Negative Breast Cancer.

Authors:  Sarah S Makhani; Antoun Bouz; Sarah Stavros; Isaac Zucker; Abigail Tercek; Katherine Chung-Bridges
Journal:  Cureus       Date:  2022-07-21

3.  Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.

Authors:  Wei Peng; Wei Tang; Jian-Di Li; Rong-Quan He; Jia-Yuan Luo; Zu-Xuan Chen; Jiang-Hui Zeng; Xiao-Hua Hu; Jin-Cai Zhong; Yang Li; Fu-Chao Ma; Tian-Yi Xie; Su-Ning Huang; Lian-Ying Ge
Journal:  PeerJ       Date:  2022-07-12       Impact factor: 3.061

4.  Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?

Authors:  Leqian Guo; Guilan Xie; Ruiqi Wang; Liren Yang; Landi Sun; Mengmeng Xu; Wenfang Yang; Mei Chun Chung
Journal:  BMC Cancer       Date:  2021-06-19       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.